2551-54-4

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 78036-47-2 (1E,1'E)-N,N'-(ethane-1,2-diyl)bis(1-(4-bromophenyl)methanimine) 

Downstream Products

• 2513-56-6 1,3-bis-(4-bromo-benzyl)-2-(3-iodo-phenyl)-imidazolidine 
• 2571-30-4 1,3-bis-(4-bromo-benzyl)-2-phenyl-imidazolidine 
• 2513-57-7 2-[1,3-bis-(4-bromo-benzyl)-imidazolidin-2-yl]-phenol 
• 2551-56-6 1,3-bis-(4-bromo-benzyl)-2-trichloromethyl-imidazolidine 
• 3403-10-9 1-[1,3-bis-(4-bromo-benzyl)-imidazolidin-2-yl]-[2]naphthol 
• 2571-33-7 2-[9]anthryl-1,3-bis-(4-bromo-benzyl)-imidazolidine 
• 2551-58-8 1,3-bis-(4-bromo-benzyl)-2-isopropyl-imidazolidine 
• 2513-53-3 1,3-bis-(4-bromo-benzyl)-2-(4-bromo-phenyl)-imidazolidine 
• 2513-55-5 1,3-bis-(4-bromo-benzyl)-2-(3-chloro-phenyl)-imidazolidine 
• 2551-57-7 1,3-bis-(4-bromo-benzyl)-2-propyl-imidazolidine 
• 2513-58-8 4-[1,3-bis-(4-bromo-benzyl)-imidazolidin-2-yl]-phenol 
• 2571-31-5 1,3-bis-(4-bromo-benzyl)-2-(4-nitro-phenyl)-imidazolidine 
• 2513-60-2 1,3-bis-(4-bromo-benzyl)-2-(3-nitro-phenyl)-imidazolidine 
• 2513-54-4 1,3-bis-(4-bromo-benzyl)-2-(2-chloro-phenyl)-imidazolidine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1

The rise in multidrug resistant (MDR) cases of tuberculosis (TB) has led to the need for the development of TB drugs with different mechanisms of action. The genome sequence of Mycobacterium tuberculosis (Mtb) revealed twenty different genes coding for cy

Synthesis and biological evaluation of novel substituted-imidazolidine derivatives

A series of newer substituted-imidazolidine derivatives 3a-k were synthesized and assayed in vivo to investigate their anti-inflammatory, analgesic and antiulcer activity. The results of biological evaluation revealed that the three compounds, 4-[1,3-bis(4-hydroxy-3-methoxybenzyl)-2- imidazolidinyl]phenyldiethylamine (3g), 4-[1,3-bis(3-Ethoxy-4-hydroxybenzyl)-2- imidazolidinyl] phenyldiethylamine (3h) and 4-(1,3-bis(benzo[d][1,3]dioxol-5- ylmethyl)-4-methylimidazolidin-2-yl)-N,N-diethylbenzenamine (3j) were good in their anti-inflammatory and analgesic actions. Additionally these derivatives showed superior GI safety profile as compared to that of the standard drug in terms of low severity index. The results are statistically treated for its significance.

Synthesis, antimicrobial activity and structure-activity relationship study of N,N-dibenzyl-cyclohexane-1,2-diamine derivatives

We report herein synthesis and antimicrobial activity of a series of N,N-dibenzyl-cyclohexane-1,2-diamine derivatives. In order to study the structure-activity relationship of substituted dibenzyl-cyclohexane-1,2-diamine derivatives, 44 structurally diverse compounds were synthesized and tested against Gram-positive and Gram-negative bacterial strains. Among them, compounds 17-20, 26, 37, 38 were found to be more active than tetracycline with MIC value ranging 0.0005-0.032 μg/mL and no hemolysis upto 1024 μg/mL in mammalian erythrocytes was observed. Some of the compounds have also shown very promising antifungal activity against Candida albicans, Candida glabrata and Geotrichum candidium.